Suicides in Japan have decreased in light of the COVID-19 lockdown. According to The Guardian, “the suicide rate in Japan fell by 20% in April compared with the same time last year, the biggest drop in five years.” The stay-at-home mandates affected about 40% of suicide prevention organizations that shut down or reduced workers’ hours. Also seeming to contribute to this drop includes the lack of commuting vs many people working long hours in the office.

In May, The National Suicide Hotline Designation Act, a bipartisan bill, passed in the US Senate to make the national suicide prevention hotline a 3-digit number. Currently, the hotline is only accessible by the usual 10-digit number 1-800-273-TALK (8255). (If we’re honest, is not that easy to remember.) Should the bill pass in the House and get signed by the president, the number would be 9-8-8, however, the 10-digit number would still be valid.

A study published in General Hospital Psychiatry found that use of antidepressants among patients hospitalized with heart failure (HF) is associated with “minor depression, history of major depression, younger age, unemployment, white race, nonischemic heart failure, polypharmacy, and functional incapacity.” The study, held from 2014-2016, had 400 patients with HF enrolled and found that there was no increase in the patients with major depression taking antidepressants compared with those who did not have depression.

Study shows atypical antipsychotics pose a higher risk for cardiac arrest

The New York Times has reported that a recent study found atypical antipsychotics, which include the friendly family of Clozaril, Abilify, Risperdal, Zyprexa, and Seroquel (maybe Saphris soon), can increase a patient’s risk of dying from cardiac arrest twofold.

The study published in The New England Journal of Medicine also concluded that the risk of death from the psychotropic medications isn’t high. However, an editorial also published in the same issue “urged doctors to limit their prescribing of antipsychotic drugs, especially to children and elderly patients, who can be highly susceptible to the drugs’ side effects.”

A U.S. News & World Report article linked to the FDA’s atypical antipsychotics page for further patient information. If you’re on an atypical, I’d recommend reading each word in the patient safety info that applies to you. Proofreaders like me shouldn’t be the only ones tortured with reading all the fine print. *winks*